CPC
LCTX icon

Cookson Peirce & Co’s Lineage Cell Therapeutics LCTX Stock Holding History

Cookson Peirce & Co’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-250,000
Closed -$113K – 305
2025
Q1 		$113K Buy
+250,000
New +$147K 0.01% 264

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Cookson Peirce & Co's LCTX Position: Q2 2025 in Review

Cookson Peirce & Co sold out of Lineage Cell Therapeutics (LCTX) in Q2 2025, closing a stake of 250,000 shares — an estimated $113K sold.

Cookson Peirce & Co first reported a position in LCTX in Q1 2025 and held it in 1 quarter. The position peaked at $113K in Q1 2025. 129 funds tracked by Wall St. Rank hold LCTX as of Q2 2025.

  • Cookson Peirce & Co reported no remaining Lineage Cell Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cookson Peirce & Co sold 250,000 Lineage Cell Therapeutics shares in Q2 2025, an estimated $113K.
  • Cookson Peirce & Co first reported a position in Lineage Cell Therapeutics in Q1 2025 and held it in 1 quarter.
  • Cookson Peirce & Co's Lineage Cell Therapeutics position peaked at $113K in Q1 2025.
  • 129 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2025.

Based on Cookson Peirce & Co's 13F filing for Q2 2025, filed 30 Jul 2025.